TRACT Therapeutics, Inc. Receives Orphan-Drug Designation for TRK-001 from the U.S. Food and Drug Administration for the Prevention of Graft Rejection Following Solid Organ Transplantation
CHICAGO (PRWEB) NOVEMBER 19, 2020 TRACT Therapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s investigational candidate, TRK-001, for its potential to prevent graft rejection following solid organ transplantation. TRK-001 is an autologous regulatory T-cell therapy that utilizes a patient’s Continue reading